Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00696
|
|||||
| Drug Name |
Phenoxybenzamine
|
|||||
| Synonyms |
2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane; 688A; A 688; Bensylyt; Bensylyt NEN; Bensylyte; Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine; Benzylyt; Dibenylene; Dibenylin; Dibenyline; Dibenziran; Dibenzylene; Dibenzylin; Dibenzyline (TN); Dibenzyran; Fenossibenzamina; Fenossibenzamina [DCIT]; Fenoxibenzamina; Fenoxibenzamina [INN-Spanish]; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine; N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine; N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine; N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine; POB HCl; Phenoxybenzamine (INN);Phenoxybenzamine [INN:BAN]; Phenoxybenzamine Hcl; Phenoxybenzaminum; Phenoxybenzaminum [INN-Latin]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Malignant phaeochromocytoma [ICD11: 2D11.1] | Approved | [1] | |||
| Benign prostatic hypertrophy [ICD11: GA90] | Approved | [1] | ||||
| Malignant essential hypertension [ICD11: BA00] | Approved | [1] | ||||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H22ClNO
|
|||||
| Canonical SMILES |
CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2
|
|||||
| InChI |
InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3
|
|||||
| InChIKey |
QZVCTJOXCFMACW-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 59-96-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 303.8 | Topological Polar Surface Area | 12.5 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
4.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10529050
, 11121824
, 11122304
, 11335975
, 11361214
, 11363032
, 11363272
, 11365594
, 11365834
, 11368156
, 11368396
, 11371195
, 11371196
, 11373757
, 11374297
, 11376318
, 11376558
, 11462186
, 11466972
, 11468092
, 11485565
, 11486803
, 11489631
, 11492584
, 11494192
, 14873959
, 26752309
, 26752310
, 29223852
, 4448492
, 46507191
, 47291177
, 47365231
, 47515348
, 47662322
, 47810788
, 47885450
, 48185031
, 48185032
, 48259269
, 48334533
, 48416417
, 49698954
, 49893224
, 50105233
, 50105234
, 50319296
, 7980292
, 8152929
, 9639
|
|||||
| ChEBI ID |
CHEBI:8077
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | Phenoxybenzamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.